In-transit metastases (ITM) in melanoma present a significant therapeutic challenge due to their advanced stage and complex clinical nature. From traditional management with surgical resection, ITM treatment has evolved with the advent of systemic therapies such as immune checkpoint inhibitors and targeted therapies, which have markedly improved survival outcomes. This study aims to review and highlight the efficacy of both systemic and locoregional treatment approaches for ITM. Methods include a comprehensive review of clinical studies examining the impact of treatments like immune checkpoint inhibitors, targeted therapies, Isolated Limb Perfusion, and electrochemotherapy. The results indicate that combining systemic therapies with locoregional treatments enhances both local disease control and overall survival rates. The introduction of modern immunotherapies has not diminished the effectiveness of locoregional therapies but rather improved patient outcomes when used in conjunction. The conclusions emphasize that a multidisciplinary approach integrating systemic and locoregional therapies offers a promising strategy for optimizing the management of ITM in melanoma patients. This integrated treatment model not only improves survival rates but also enhances the quality of life for patients, suggesting a shift in standard care practices toward more comprehensive therapeutic regimens.
黑色素瘤的移行转移因其晚期阶段和复杂的临床特征构成了显著的治疗挑战。从传统的手术切除管理方式，移行转移的治疗已随着免疫检查点抑制剂和靶向治疗等系统性疗法的出现而发展，这些方法显著改善了患者的生存结局。本研究旨在回顾并强调系统性治疗与局部区域治疗在移行转移中的疗效。研究方法包括对临床研究进行全面综述，探讨免疫检查点抑制剂、靶向治疗、隔离肢体灌注和电化学疗法等治疗手段的影响。结果表明，系统性治疗与局部区域治疗的结合能够增强局部疾病控制并提高总体生存率。现代免疫疗法的引入并未削弱局部区域治疗的效果，反而在联合应用时改善了患者的治疗结局。结论强调，整合系统性治疗与局部区域治疗的多学科策略为优化黑色素瘤移行转移的管理提供了前景广阔的治疗方案。这一综合治疗模式不仅提高了生存率，还改善了患者的生活质量，提示标准临床实践正朝着更全面的治疗方案转变。
Therapeutic Treatment Options for In-Transit Metastases from Melanoma
肿瘤(癌症)患者之家